Launch of VICTOR(TM) X Multilabel Plate Reader Platform Offers Improved Flexibility to Drug Discovery and Research Customers ST. LOUIS–PerkinElmer, Inc. (NYSE: PKI – News), a global leader in Health Sciences and Photonics, today announced the launch of its VICTOR™ X Multilabel Plate Reader platform at the Society for Biomolecular Sciences’ (SBS) 14th Annual Conference and Exhibition. The new VICTOR X platform will deliver to customers increased flexibility, while its enhanced versatility will enable support of new applications beyond primary screening, including quality control and therapeutic research. The VICTOR X platform is the latest edition of PerkinElmer’s VICTOR series of best-in-class benchtop multilabel detection instruments, which are widely used by research labs of all sizes, including academic centers, pharmaceutical and biotech screening labs, drug discovery groups, and disease and therapeutic area research groups. “Since the VICTOR platform was launched as one of the first fully-loaded multilabel plate readers on the market, PerkinElmer has remained committed to meeting customers’ demands for a range of reliable, easy-to-use and cost-effective solutions for drug discovery and research,” said Richard Eglen, Ph.D., president, Bio-discovery, PerkinElmer, Inc. “In developing VICTOR X we drew strongly from customer feedback, leading to an enhanced product featuring upgraded software that is customizable and open-ended for ease of integration with research applications. Our customers can now more easily create a new protocol or select and run one of several pre-set application-based protocols.” The enhanced software package features: an improved “Start Wizard” for easier creation of new protocols; application-based example protocols for off-the-shelf use; and improved kinetics support for monitoring cellular and enzyme assays in real-time. The VICTOR X units are also designed to facilitate major accessory field upgrades, so users can add functionality as their needs evolve. Factors Affecting Future Performance This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow, revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers’ demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) our failure to comply with health care industry regulations; (11) economic, political and other risks associated with foreign operations; (12) our ability to retain key personnel; (13) restrictions in our credit agreements; (14) our ability to realize the full value of our intangible assets; and (15) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release. PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of $1.8 billion in 2007, has 9,100 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.